Von der Bezeugung zur narrativen Vergegenwärtigung. Fokalisierung im Reisebuch des Syrers Ḥanna Dyāb (1764)

Travelogues involve different truth claims, depending on whether their authors attempt on the one hand to convey received knowledge about entities and places, or on the other hand, present accounts of the traveler character’s own experiences. This study focuses on a travelogue from 1764 written by the Arabian Nights’ Syrian storyteller, Ḥanna Dyāb. Having written his travelogue more than 50 years after his trip to Paris, he evidently conceived of his narrative as a means to re-enact his experiences as a young traveler. To describe his particular self-staging in this autodiegetic narration “before fiction” (Paige 2011), I argue that an understanding of focalization as a graded visual mediation between the character’s inner life and the reader is needed. This approach helps one grasp how, with reference to Dyāb’s travelogue, truth is not something the traveler witnesses, but rather something the reader is invited to realize. I conclude that, with this shift from witnessing to visualization (Vergegenwärtigung), Dyāb’s travelogue fulfills a core function of literature.

Myocardial expression profiles of candidate molecules in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia compared to those with dilated cardiomyopathy and healthy controls.

BACKGROUND Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is mainly an autosomal dominant disease characterized by fibrofatty infiltration of the right ventricle, leading to ventricular arrhythmias. Mutations in desmosomal proteins can be identified in about half of the patients. The pathogenic mechanisms leading to disease expression remain unclear. OBJECTIVE The purpose of this study was to investigate myocardial expression profiles of candidate molecules involved in the pathogenesis of ARVC/D. METHODS Myocardial messenger RNA (mRNA) expression of 62 junctional molecules, 5 cardiac ion channel molecules, 8 structural molecules, 4 apoptotic molecules, and 6 adipogenic molecules was studied. The averaged expression of candidate mRNAs was compared between ARVC/D samples (n = 10), nonfamilial dilated cardiomyopathy (DCM) samples (n = 10), and healthy control samples (n = 8). Immunohistochemistry and quantitative protein expression analysis were performed. Genetic analysis using next generation sequencing was performed in all patients with ARVC/D. RESULTS Following mRNA levels were significantly increased in patients with ARVC/D compared to those with DCM and healthy controls: phospholamban (P ≤ .001 vs DCM; P ≤ .001 vs controls), healthy tumor protein 53 apoptosis effector (P = .001 vs DCM; P ≤ .001 vs controls), and carnitine palmitoyltransferase 1β (P ≤ .001 vs DCM; P = 0.008 vs controls). Plakophillin-2 (PKP-2) mRNA was downregulated in patients with ARVC/D with PKP-2 mutations compared with patients with ARVC/D without PKP-2 mutations (P = .04). Immunohistochemistry revealed significantly increased protein expression of phospholamban, tumor protein 53 apoptosis effector, and carnitine palmitoyltransferase 1β in patients with ARVC/D and decreased PKP-2 expression in patients with ARVC/D carrying a PKP-2 mutation. CONCLUSION Changes in the expression profiles of sarcolemmal calcium channel regulation, apoptosis, and adipogenesis suggest that these molecular pathways may play a critical role in the pathogenesis of ARVC/D, independent of the underlying genetic mutations.